No headlines found.
Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Globe Newswire (Thu, 13-Nov 7:00 AM ET)
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
Instil Bio trades on the NASDAQ stock market under the symbol TIL.
As of December 17, 2025, TIL stock price declined to $11.01 with 39,014 million shares trading.
TIL has a beta of 1.46, meaning it tends to be more sensitive to market movements. TIL has a correlation of 0.06 to the broad based SPY ETF.
TIL has a market cap of $74.67 million. This is considered a Micro Cap stock.
In the last 3 years, TIL traded as high as $92.00 and as low as $6.07.
The top ETF exchange traded funds that TIL belongs to (by Net Assets): VTI, VXF, DFAT, SMLF, IWC.
TIL has underperformed the market in the last year with a return of -51.1%, while the SPY ETF gained +11.8%. In the last 3 month period, TIL fell short of the market, returning -52.2%, while SPY returned +2.0%. However, in the most recent 2 weeks TIL has outperformed the stock market by returning +2.1%, while SPY returned -1.5%.
TIL support price is $10.67 and resistance is $11.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TIL shares will trade within this expected range on the day.
